Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I study of ML-007 in healthy adult and elderly subjects for treatment with neurodegenerative and neurocognitive disorders such as schizophrenia, Alzheimer's disease psychosis, and dyskinesias

Next Previous
X
Search
Trial Profile

A Phase I study of ML-007 in healthy adult and elderly subjects for treatment with neurodegenerative and neurocognitive disorders such as schizophrenia, Alzheimer's disease psychosis, and dyskinesias

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ML 007/muscarinic antagonist (Primary) ; ML-007 (Primary)
  • Indications Dyskinesias; Schizophrenia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors MapLight Therapeutics

    • Most Recent Events

    • 30 Aug 2023 New trial record
    • 24 Aug 2023 Results presented in a MapLight Therapeutics media release.
    • 24 Aug 2023 According to a MapLight Therapeutics media release, company announced successful completion of a second Phase 1 clinical trial evaluating ML-007 in neurodegenerative and neurocognitive disorders such as schizophrenia, Alzheimer's disease psychosis, and dyskinesias.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top